Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
; (12): 836-842, 2021.
Article
de Zh
| WPRIM
| ID: wpr-942965
Bibliothèque responsable:
WPRO
ABSTRACT
Surgery is the main treatment for resectable esophageal squamous cell carcinoma. However, for patients with locally advanced lesions, surgery-based comprehensive treatment is the best treatment strategy. According to the results of some randomized controlled clinical studies and meta-analysis, preoperative neoadjuvant therapy is recommended to improve the survival rate of patients. Neoadjuvant therapy includes neoadjuvant chemotherapy, chemoradiotherapy, targeted therapy and immunotherapy. Great progress has been made in neoadjuvant therapy, but there are still many clinical problems that need to be solved urgently, including the efficacy and safety of neoadjuvant therapy, the choice of neoadjuvant regimen and treatment cycle, the best combination and advantages of multimodal treatment, and the selection of responders to treatment, etc. This article provides a systematic review of the latest developments and existing controversies in neoadjuvant therapy for esophageal squamous cell carcinoma.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Tumeurs de l'oesophage
/
Oesophagectomie
/
Association thérapeutique
/
Traitement néoadjuvant
/
Chimioradiothérapie
/
Carcinome épidermoïde de l'oesophage
Type d'étude:
Clinical_trials
/
Systematic_reviews
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Gastrointestinal Surgery
Année:
2021
Type:
Article